These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38943989)

  • 1. Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition.
    Bentanachs R; Miró L; Sánchez RM; Ramírez-Carrasco P; Amat C; Alegret M; Pérez A; Roglans N; Laguna JC
    Biomed Pharmacother; 2024 Aug; 177():117067. PubMed ID: 38943989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences Affect the NRF2 Signaling Pathway in the Early Phase of Liver Steatosis: A High-Fat-Diet-Fed Rat Model Supplemented with Liquid Fructose.
    Di Veroli B; Bentanachs R; Roglans N; Alegret M; Giona L; Profumo E; Berry A; Saso L; Laguna JC; Buttari B
    Cells; 2024 Jul; 13(15):. PubMed ID: 39120278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
    Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20-Week follow-up of hepatic steatosis installation and liver mitochondrial structure and activity and their interrelation in rats fed a high-fat-high-fructose diet.
    Fouret G; Gaillet S; Lecomte J; Bonafos B; Djohan F; Barea B; Badia E; Coudray C; Feillet-Coudray C
    Br J Nutr; 2018 Feb; 119(4):368-380. PubMed ID: 29498345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ChREBP-driven DNL and PNPLA3 Expression Induced by Liquid Fructose are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High-Fat Diet-Fed Rat Model.
    Velázquez AM; Bentanachs R; Sala-Vila A; Lázaro I; Rodríguez-Morató J; Sánchez RM; Alegret M; Roglans N; Laguna JC
    Mol Nutr Food Res; 2022 Apr; 66(7):e2101115. PubMed ID: 35124887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipose Tissue Protects against Hepatic Steatosis in Male Rats Fed a High-Fat Diet plus Liquid Fructose: Sex-Related Differences.
    Bentanachs R; Blanco L; Montesinos M; Sala-Vila A; Lázaro I; Rodríguez-Morató J; Sánchez RM; Laguna JC; Roglans N; Alegret M
    Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the fecal microbiome and metabolome by resistant dextrin ameliorates hepatic steatosis and mitochondrial abnormalities in mice.
    Zhang Z; Chen X; Cui B
    Food Funct; 2021 May; 12(10):4504-4518. PubMed ID: 33885128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
    Sasaki Y; Asahiyama M; Tanaka T; Yamamoto S; Murakami K; Kamiya W; Matsumura Y; Osawa T; Anai M; Fruchart JC; Aburatani H; Sakai J; Kodama T
    Sci Rep; 2020 May; 10(1):7818. PubMed ID: 32385406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy.
    Kanno K; Koseki M; Chang J; Saga A; Inui H; Okada T; Tanaka K; Asaji M; Zhu Y; Ide S; Saito S; Higo T; Okuzaki D; Ohama T; Nishida M; Kamada Y; Ono M; Saibara T; Yamashita S; Sakata Y
    Sci Rep; 2022 Feb; 12(1):2996. PubMed ID: 35194060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yeast β-glucan reduces obesity-associated
    So SY; Wu Q; Leung KS; Kundi ZM; Savidge TC; El-Nezami H
    Am J Physiol Gastrointest Liver Physiol; 2021 Dec; 321(6):G639-G655. PubMed ID: 34643089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Measures of Dyslipidemia, Inflammation, and Oxidative Stress in Rats Fed a High-Fat/High-Fructose Diet.
    Feillet-Coudray C; Fouret G; Vigor C; Bonafos B; Jover B; Blachnio-Zabielska A; Rieusset J; Casas F; Gaillet S; Landrier JF; Durand T; Coudray C
    Lipids; 2019 Jan; 54(1):81-97. PubMed ID: 30767221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the expression of cholesterol transporters by lipid-lowering drugs ezetimibe and pemafibrate in rat liver and intestine.
    Tanaka Y; Kamisako T
    Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166215. PubMed ID: 34265370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
    Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
    Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between 12α-hydroxylated bile acids and hepatic steatosis in rats fed a high-fat diet.
    Hori S; Abe T; Lee DG; Fukiya S; Yokota A; Aso N; Shirouchi B; Sato M; Ishizuka S
    J Nutr Biochem; 2020 Sep; 83():108412. PubMed ID: 32534424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
    Kimura A; Kamimura K; Ohkoshi-Yamada M; Shinagawa-Kobayashi Y; Goto R; Owaki T; Oda C; Shibata O; Morita S; Sakai N; Abe H; Yokoo T; Sakamaki A; Kamimura H; Terai S
    Biochem Biophys Res Commun; 2022 Mar; 596():76-82. PubMed ID: 35121372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.